A Trich-y question: Should trichomonas vaginalis infection be reportable?

Sexually Transmitted Diseases

Volumn 40, Issue 2, 2013, Pages 113-116

  Hoots, Brooke E ^a,b   Peterman, Thomas A ^a   Torrone, Elizabeth A ^a   Weinstock, Hillard ^a   Meites, Elissa ^a   Bolan, Gail A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; TINIDAZOLE;

ATTITUDE TO ILLNESS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH DISPARITY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MEDICAL CARE; NONSPECIFIC URETHRITIS; NOTE; NUCLEIC ACID AMPLIFICATION; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREMATURE LABOR; PREVALENCE; PRIMARY PREVENTION; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SOCIAL MARKETING; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VAGINITIS;

ADOLESCENT; ADULT; DISEASE NOTIFICATION; FEMALE; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; UNITED STATES;

EID: 84872967208     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31827c08c3     Document Type: Note

References (30)

1. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6-10.
2. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007; 45:1319-1326.
3. Hobbs MM, Sena AC, Swygard H, et al. Trichomonas vaginalis and trichomoniasis. In: Holmes KK, ed. Sexually Transmitted Diseases, 4th ed. New York: McGraw-Hill Medical, 2008.
4. Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the APTIMA(R) Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012.
5. German RR, Lee LM, Horan JM, et al. Updated guidelines for evaluating public health surveillance systems: Recommendations from the Guidelines Working Group. MMWR Recomm Rep 2001; 50: 1-35; quiz CE1-7.
6. Teutsch SM, Thacker SB. Planning a public health surveillance system. Pan American Health Organization. Epidemiol Bull 1995; 16:1-6.
7. Helms DJ, Mosure DJ, Metcalf CA, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis 2008; 35:484-488.
8. Joyner JL, Douglas JM Jr, Ragsdale S, et al. Comparative prevalence of infection with Trichomonas vaginalis among men attending a sexually transmitted diseases clinic. Sex Transm Dis 2000; 27:236-240.
9. Schwebke JR, Hook EW 3rd. High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: Implications for screening and urethritis management. J Infect Dis 2003; 188:465-468.
10. Shuter J, Bell D, Graham D, et al. Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis 1998; 25:303-307.
11. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002; 34:1406-1411.
12. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-infected women: Are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003; 30:839-843.
13. Watts DH, Springer G, Minkoff H, et al. The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: Longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr 2006; 43:161-168.
14. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997; 24:353-360.
15. Sutton MY, Sternberg M, Nsuami M, et al. Trichomoniasis in pregnant human immunodeficiency virusYinfected and human immunodeficiency virusYuninfected congolese women: Prevalence, risk factors, and association with low birth weight. Am J Obstet Gynecol 1999; 181:656-662.
16. Krieger JN, Verdon M, Siegel N, et al. Natural history of urogenital trichomoniasis in men. J Urol 1993; 149:1455-1458.
17. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
18. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008; 197:548-554.
19. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344:246-248.
20. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
21. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-1022.
22. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009; 36:11-16.
23. Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT Study Group. Sex Transm Dis 2000; 27:446-451.
24. Owusu-Edusei K Jr, Tejani MN, Gift TL, et al. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005. Sex Transm Dis 2009; 36:395-399.
25. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19.
26. Sanchez J, Campos PE, Courtois B, et al. Prevention of sexually transmitted diseases (STDs) in female sex workers: Prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis 2003; 30:273-279.
27. Workowski KA, Berman S, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
28. Watt L, Jennison RF. Incidence of Trichomonas vaginalis in marital partners. Br J Venerol Dis 1960; 36:163-166.
29. Kaiser Family Foundation. The Kaiser survey on public knowledge and attitudes about STDs other than AIDS. Available at:http://www.kff.org/ youthhivstds/1206-stdtop.cfm. Accessed May14, 2012.
30. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis 2012; 18:939-943.